Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 May 5;20(5):e0322479.
doi: 10.1371/journal.pone.0322479. eCollection 2025.

The epidemiological trends and projected future of primary sclerosing cholangitis by 2040: An updated meta-analysis and modeling study

Meysam Olfatifar  1 , Mohsen Rajabnia  2 , Amir Sadeghi  3 , Amirhassan Rabbani  4 , Shabnam Shahrokh  3 , Mohammad Amin Habibi  5 , MehdiSure Pezeshgi Modarres  1 , Mohammad Reza Zali  3 , Hamidreza Houri  6
Affiliations
Meta-Analysis

The epidemiological trends and projected future of primary sclerosing cholangitis by 2040: An updated meta-analysis and modeling study

Meysam Olfatifar et al. PLoS One. .

Abstract

Background and aims: Primary sclerosing cholangitis (PSC) exhibits varying incidence and prevalence rates across different regions; however, comprehensive global studies examining its geographic distribution and future trends are scarce. This study presents an updated meta-analysis through 2024 and projects the global and regional prevalence of PSC from 2024 to 2040 using an illness-death multi-state model.

Methods: We conducted a thorough systematic search across multiple databases to identify all primary studies published until 2024 that reported on the incidence, prevalence, and mortality rates of PSC in various regions. Using the gathered data, we developed an illness-death model to forecast the future prevalence of PSC, covering the years 2024-2040.

Results: Our meta-analysis revealed that the global pooled incidence and prevalence rates of PSC are 0.65 and 7.52 per 100,000 persons, respectively. Projections indicate that the global prevalence of PSC will rise to 22.98 cases per 100,000 (95% CI: 21.0-24.95), corresponding to an overall increase of 28.3%. Specifically, North America is forecasted to experience a 5.45% increase in PSC cases, reaching 24.76 cases per 100,000 (95% CI: 19.63-29.88), while Western Europe is anticipated to see a more pronounced rise of 28.79%, resulting in a prevalence of 21.48 cases per 100,000 (95% CI: 18.3-24.65) by 2040.

Conclusions: Our findings indicate a substantial rise in the number of individuals affected by PSC in recent years and estimate a significant future burden of the disease.

PubMed Disclaimer

Conflict of interest statement

The authors declared no conflict of interest.

Figures

Fig 1
Fig 1. PRISMA flow diagram indicating the steps in study selection.
Fig 2
Fig 2. Forest plots representing the global and regional incidence rate of PSC.
Fig 3
Fig 3. Forest plots representing the global and regional prevalence rate of PSC.
Fig 4
Fig 4. Forest plots representing the global and regional mortality rate of PSC.
Fig 5
Fig 5. Prevalent PSC cases across the world from 1995–2040.
Fig 6
Fig 6. Prevalent PSC cases in High-income North America and Western Europe from 2019–2040.
Fig 7
Fig 7. Prevalent PSC cases in Australasia and High-income Asia-Pacific from 2019–2040.
See this image and copyright information in PMC

References

    1. Chapman MH, Thorburn D, Hirschfield GM, Webster GGJ, Rushbrook SM, Alexander G, et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019;68(8):1356–78. doi: 10.1136/gutjnl-2018-317993 - DOI - PMC - PubMed
    1. Karlsen TH, Vesterhus M, Boberg KM. Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis. Aliment Pharmacol Ther. 2014;39(3):282–301. doi: 10.1111/apt.12581 - DOI - PubMed
    1. Loftus EV Jr, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54(1):91–6. doi: 10.1136/gut.2004.046615 - DOI - PMC - PubMed
    1. de Vries AB, Janse M, Blokzijl H, Weersma RK. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol. 2015;21(6):1956–71. doi: 10.3748/wjg.v21.i6.1956 - DOI - PMC - PubMed
    1. Mitchell SA, Thyssen M, Orchard TR, Jewell DP, Fleming KA, Chapman RW. Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study. Gut. 2002;51(4):567–73. doi: 10.1136/gut.51.4.567 - DOI - PMC - PubMed

Publication types

LinkOut - more resources